/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.
A new immunotherapy from China may offer another option for post-chemoradiotherapy treatment in patients with unresectable with stage III non-small cell lung cancer.